AcouSort’s role in the Blue4Therapy project expands - SEK 700,000 in additional revenue in 2022
The Blue4Therapy project was initiated in May 2020 with the ambition to develop clinical applications in cell therapy and stem cell treatments – two areas with great commercial potential. Behind the project are the University of Southern Denmark, BlueCell Therapeutics, Novozymes and AcouSort. AcouSort's contribution to the project has been to develop a module for the purification of stem cells in a point-of-care environment.
Blue4Therapy’s goal is to develop a platform to separate out specific stem cells, so-called blue cells, from the patient’s own adipose tissue for the treatment of various medical conditions. The first area of use is the treatment of erectile dysfunction caused by prostate cancer treatment, where AcouSort contributes with its separation technology enabling isolation and enrichment of stem cells in an efficient way. The goal is to develop a product that can be used to extract stem cells from the patient's own adipose tissue.
The partner company BlueCell Therapeutics in Copenhagen is responsible for developing the different therapies and was originally also supposed to develop the first complete prototype. BlueCell has now commissioned AcouSort to carry out this work, which will generate revenues of SEK 700,000 in 2022 in addition to the EUR 300,000 that AcouSort receives from Vinnova within the framework of the project.
Future commercialization primarily rests on BlueCell’s plans for an international establishment of clinics using this unique cell therapy and where AcouSort could create recurring revenue streams through the sale of the company’s single-use separation module.
“The Blue4Therapy project has been incredibly exciting and instructive and has meant that AcouSort has advanced its positions in the field of cell therapy. The project is fully in line with our strategy and vision to become the leading supplier of components for the preparation of clinical samples for both diagnostics and therapy. The fact that we now have an even larger assignment within the framework of the project is particularly gratifying and a sign of strength for AcouSort as a company,” says AcouSort’s CEO Torsten Freltoft.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
For further information about BlueCell Therapeutics, please contact:
Søren P. Sheikh, CEO
Phone: +45 2138 0410
E-mail: sheikh@blue-cell.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.